Influenza Vaccine Post Allogeneic Transplant
Stopped early · Not applicable
Conditions studied: Hematopoietic Stem Cell Transplant, Hematologic Malignancy
In brief
Study Design: This is a randomized, single center study to evaluate immune responses to the seasonal influenza vaccine in allogeneic hematopoietic stem cell transplant (HSCT) recipients who receive one vaccine or two vaccine doses one month apart. In addition, a cohort of healthy adult volunteers will be recruited as controls to confirm immune response to a single influenza vaccine.
Key facts
- Study ID
- NCT01215981
- Run by
- Masonic Cancer Center, University of Minnesota
- People needed
- 68
- Starts
- 2010-09-01
- Expected to finish
- 2011-06-01
- Last updated by the study team
- 2017-12-28
Who can join
Age: 1 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Patient Population
- HSCT recipients who are greater than 60 days post transplant.
- Age 6 months and older who are greater than 60 days post post allogeneic hematopoietic cell transplant
- Show neutrophil recovery, platelet count > 50,000/mm3 (may be transfused), no known disease relapse
- No history of previous allergic reaction to influenza vaccine, known egg allergy or Guillan-Barre Syndrome
- No flu vaccine in previous 4 months, no Campath in previous 6 months, no intravenous immune globulin (IVIG) in previous 3 months
- Controls:
- Age 18 to 50 years
- No history of previous allergic reaction to influenza vaccine, known egg allergy or Guillan-Barre Syndrome
- No flu vaccine in previous 4 months
Where it is running
- Masonic Cancer Center, University of Minnesota — Minneapolis, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.